嗜麦芽假单胞菌的碱性蛋白酶基因在大肠杆菌中的克隆与表达

用pUCl8质粒作为载体,将嗜麦芽假单胞菌(Psedeomonas maltophilia P27)的碱性蛋白酶基因克隆到大肠杆菌(E．Coli TGI)中,得到3株能分泌碱性蛋白酶的阳性克隆G1,G2和G3。其中G3所分泌的碱性蛋白酶活性最高,大约是出发菌株的3—4倍,对3株阳性克隆所含的重组质粒psJl,psJ2和psJ3进行限制酶酶切分析表明,酶活最高的阳性克隆G3所含的重组质粒psJ3的插入片段最小,大约是2．8kb;其它两株的重组质粒pSJl和pSJ2含有同样大小的插入片段,约为5．5kb。     

人粒细胞－巨噬细胞集落刺激因子在大肠 杆菌中的克隆与表达

利用基因重组技术构建人粒细胞－巨噬细胞集落刺激因子(bGM—CSF)的高效表达菌株E．Coli HB101／pZw．GM47,经酶切电泳、DNA测序、SDS—PAGE、Western印迹及生物活性测定等分析鉴定,证明能特异性表达有生物活性的14kDaGM—CSF,表达水平达40％以上,比活性高达5×10⁷u／mg．具有良好的开发应用前景。     

枯草杆菌中性蛋白酶基因在大肠杆菌中的表达

蛋白酶是枯草杆菌(Bacillus subtilis)产生的具有重要工业价值的水解酶。对蛋白酶基因的分离与高效率表达一直是基因工程研究领域的重要内容之一^[1-4]。蛋白酶基因的筛选可采用不同的方法,如“免疫法”、“DNA 杂交法”、“遗传互补法”等。大肠杆菌(Escherichia coli)是基因工程中最常用的宿主菌, 若能以E．Coli作为筛选蛋白酶基因的宿主苗,那么使用E．Coli的常规载体,便可直接获得完整的蛋白 酶基因。枯草杆菌的蛋白酶基因能否在大肠杆菌中表达．则是实现这一目标的关键。Koide等人^[5]报道过枯草杆菌的胞内丝氨酸蛋白酶基因在大肠杆菌中的表达。转化细胞在含有脱脂牛奶的平板上可产生十分微弱的水解圈。Ikeraara等人^[6]将Subtilisin E(枯草杆菌蛋白酶E)插人大肠杆菌的表达载体,具有活性的Subtilisin E便可分泌到大肠杆菌的细胞周质中。吴汝平撰文指出^[7]。克隆的枯草杆菌蛋白酶基因不能在大肠杆菌中表达。是因为大肠杆菌不能转录枯草杆菌的促使生长调节基因。Wang等人^[8]则认为,在大肠杆菌中观察不到野生型的中性蛋白酶基因E(nprE)的表达。是因为nprE的表达产物对大肠杆菌有致死作用．除去该基因上的核糖体结合位点,nprE便能在大肠杆菌中低水平表达,并能将表达产 物分泌至胞外。由上可知．枯草杆菌的蛋白酶基因能否在大肠杆菌中表达以及表达的位置仍然是一个众说纷纭的问题,这一问题也正是能否用大肠杆菌作为宿主菌筛选蛋白酶基因的关键。     

par区域的克隆及其对质粒pUC9稳定性的影响

将pSC1o1上的par区域克隆到载体pUC9上,得重组质粒pEC302。将puC9和Hpkc302分别转入E．Coli HB 101,在无机培养基M₉中试验两者的稳定性,结果发现E．Coli IBIoi(：puc9>传代培养40代后质粒几乎全部丢失,而E．Coli HBIOI(pEC302)的质粒全部存在。并且发现质粒的稳定性与宿主菌的recA基因有关。     

百脉根Rac1蛋白多克隆抗体的制备与应用

Rop基因在豆科植物与根瘤菌共生互作过程中发挥重要作用。该研究以模式豆科植物百脉根根系cDNA为模板,扩增得到百脉根的1个Rop基因（Rac1）,将其连接到原核表达载体pET28a,转化获得Rac1基因的大肠杆菌BL21（DE3）工程菌。优化Rac1蛋白诱导表达条件,亲和吸附法纯化蛋白,制备Rac1多克隆抗体,并应用该抗体检测Rac1过表达转基因植株中Rac1蛋白的表达水平。结果显示：（1）经双酶切和测序鉴定,成功构建pET28a Rac1原核表达载体。（2）Rac1蛋白的最佳诱导表达条件为：IPTG浓度0.1 mmol/L、温度20 ℃、时间6 h,重组蛋白以可溶形式高效表达;纯化的Rac1蛋白经SDS PAGE检测,目的条带大小为25 kD左右,且条带清晰、单一无杂带。（3）Western blotting显示,制备的多克隆抗体能特异识别其对应的抗原,且效价较高。（4）通过农杆菌介导的毛根转化法获得Rac1过表达植株的阳性毛根,提取阳性毛根总蛋白,Western blotting分析显示过表达植株中Rac1蛋白表达量显著高于空载体对照,从翻译水平证实过表达载体构建的有效性。该研究制备的Rac1多克隆抗体能够高效特异地检测来源于百脉根体内的Rac1蛋白,这将为进一步开展Rac1在共生信号转导途径中的生物学功能研究提供有利工具。     

1株来自海洋的芽胞杆菌dhs-330转座突变库的构建及表面活性相关基因的克隆

为研究产生物表面活性剂的海洋芽胞杆菌dhs-330合成活性产物的分子机制,应用质粒pIC333介导的mini-Tn10转座子随机突变技术,构建了芽胞杆菌dhs-330的突变体库。通过表面活性测定和反向PCR克隆,从300个突变株中筛选出产表面活性剂水平提高的突变株2株,分别在ycsG和yvkC基因发生插入突变;表面活性降低的突变株4株,分别在fenC、yrkF、kinE和sigD基因发生插入突变。这些基因可能与芽胞杆菌dhs-330中表面活性剂的合成代谢和调控有关。     

大肠杆菌galK基因与gPt基因在爪蟾卵母细胞中的表达

把含有E．Coil gal K基因和gpt基因的几种重组质粒显微注射到爪蟾(Xencpus Laevis)卵母细胞的核中,用淀粉凝胶电泳检测到了细菌基因的表达产物。E．Coli gal K基因和gpt基因在爪瞻卵母细胞中的表达依赖于SV40病毒早期启动子的存在,而小鼠β-珠蛋白启动子在爪蟾卵母细胞中缺乏活性。此外,增强子在爪蟾卵母细胞中对细菌基因的活性有较为明显的增强作用。     

依赖PrfA转录调控的单核细胞增生李斯特菌毒力基因inlC启动子结构特点的初步研究

为了研究单核细胞增生李斯特菌毒力基因启动子的结构特点与转录调控因子PrfA蛋白之间的关系,应用PCR定点突变和重组PCR技术缺失了该菌毒力基因inlC启动子上可能与PrfA蛋白结合以及诱发转录起始相关的碱基序列,构建了一系列突变启动子与lacZ报告基因融合表达质粒, 使lacZ基因的表达置于inlC突变启动子下,并分别电转化单核细胞增生李斯特菌野生株P14、PrfA蛋白高表达突变株P14a 和prfA基因等位缺失突变株A42中,检测相应的β-半乳糖苷酶活性。结果表明：位于inlC启动子转录起始点下游22bp 处的一段17bp的类似PrfA蛋白结合序列TTAACAGCGTTTGTTAA并没有增强和抑制PrfA转录调控活性的功能;甚至将其改造成“完美的” PrfA蛋白结合序列TTAACATTTGTTAA后,也不影响inlC依赖于PrfA的转录活性地表达;但是,如果缺失inlC启动子上原始的PrfA蛋白结合序列,则使inlC依赖于PrfA的转录活性完全丧失;另外,单核细胞增生李斯特菌毒力基因inlC和plcA 依赖于PrfA的转录活性的表达也与启动子上PrfA蛋白结合区(PrfA-box)距离-10区的碱基个数有关:最适为22或23bp,长于23bp或短于22bp的突变启动子的依赖PrfA的转录活性大大降低,甚至没有活性。说明除PrfA蛋白结合序列外,受PrfA调控的毒力基因启动子上还可能存在其它尚未阐明的结构和序列影响PrfA蛋白的结合以及启动转录表达。     

苯唑西林敏感、mecA基因阳性的猪源金黄色葡萄球菌的流行、分子分型及耐药性研究

[目的] 为了解我国猪源苯唑西林敏感-mecA阳性金黄色葡萄球菌（Oxacillin-susceptible,mecA-positive Staphylococcus aureus,OS-MRSA）的流行情况、菌株分子特征及耐药性,本研究对我国中西部4个省份（甘肃、陕西、河南和广西）的9个规模化养猪场进行鼻腔拭子样本采集。[方法] 运用PCR扩增nuc和mecA基因及苯唑西林耐药性检测对OS-MRSA菌株进行分离鉴定。然后对分离所得的OS-MRSA菌株进行26种毒素编码基因、16种抗生素耐药性以及spa、MLST和SCCmec分型检测。[结果] 结果表明,采集的884份样本中,67份样本7.6%（67/884）分离到金黄色葡萄球菌,包括50株甲氧西林敏感菌株（Methicillin-sensitive Staphylococcus aureus,MSSA）、8株苯唑西林耐受-mecA阳性金黄色葡萄球菌（Oxacillin-resistant mecA-positive,OR-MRSA）和9株OS-MRSA菌株。26种被检毒素编码基因中有9种毒素编码基因被检出,其中hla基因检出率最高,其次为hld、hlb、hlg、sei、sem、seg、sen和seo。此外,67株分离株中仅有16株携带肠毒素编码基因,其中OR-MRSA和OS-MRSA菌株分别占37.5%（6/16）和50.0%（8/16）,且携带毒素编码基因的菌株克隆型均为ST9-t899。16种所测试抗生素中,菌株对12种抗生素表现为耐药,其中MSSA、OR-MRSA和OS-MRSA分离株分别主要对1-8、10-12和7-11种抗生素耐药。所有分离株共有4种克隆型ST398-t571、ST9-t899、ST398-t034和t11241,其中ST9-t899为MRSA菌株唯一克隆型和ST398-t571为MSSA优势克隆型。除4株分离株未检测到SCCmec分型外,IV_b（76.5%,13/17）是MRSA分离株的唯一分型。[结论] 结果表明,我国猪源MRSA分离株对苯唑西林药物敏感性发生了改变,出现了较多的苯唑西林敏感菌株。此外,MSSA和MRSA分离株优势克隆型分别为ST398-t571和ST9-IVb-t899。研究还发现,克隆型与毒素编码基因有显著相关性,携带毒素编码基因的菌株克隆型均为ST9-t899。通过了解我国猪源MSSA、OR-MRSA和OS-MRSA的流行、分子特征和耐药性,可以为我国猪源金黄色葡萄球菌的防控提供数据支持。     

PC-1分子转录激活功能研究

PC-1基因是在人前列腺癌细胞中克隆的新基因,表达水平随前列腺癌恶性程度增加而升高,其表达产物具有转录因子的一些特征.为研究PC-1分子的转录激活功能,首先应用酵母双杂交系统将PC-1全长以及不同区段的cDNA克隆到表达载体pAS2-1中,然后分别转化酵母细胞株CG-1945. lacZ和His3报告基因激活的检测结果表明,该分子具有转录激活活性并将该活性定位于N端的46个氨基酸区域.此外,将PC-1分子不同区段的cDNA分别克隆至表达载体pZHO1中,将它们与报告基因质粒pTRE-luc共转染哺乳动物细胞COS7和C4-2,Firefly荧光素酶相对活性的检测结果表明,该分子N端的46个氨基酸区域具有转录激活活性.     

人源抗滋养层细胞表面抗原?鄄2基因工程抗体Fab的制备及特性分析

应用噬菌体抗体库技术制备全人源抗滋养层细胞表面抗原-2(Trop-2)特异性Fab抗体片段．抗体库经细胞筛选和固相抗原筛选,获得特异性的阳性克隆．阳性载体经核酸序列分析后,构建工程菌,经IPTG诱导表达,SDS-PAGE和Western blot分析,呈现28 ku和32 ku大小的两条蛋白质条带．Fab分子经流式细胞术、细胞免疫荧光检测,结果表明,Fab能够与BxPc3细胞膜蛋白特异性结合,而与NIH3T3细胞不结合．免疫共沉淀与质谱分析结果表明,该Fab分子能够与Trop-2蛋白特异性结合．免疫组化显示,该抗体可结合胰腺癌细胞膜蛋白,在细胞培养液中加入Fab,能够抑制BxPc3细胞的生长．以上研究结果提示,该抗体有望成为胰腺癌临床影像诊断或治疗的候选分子．     

从大容量噬菌体抗体库中筛选抗Acr蛋白人源单链抗体

目的:从天然的大容量噬菌体抗体库中筛选特异的抗结核分枝杆菌晶体蛋白( alpha-crystallin Acr)的人源抗体.方法:以结核分枝杆菌Acr蛋白包被免疫管,通过对噬菌体抗体库进行4轮“吸附-洗脱-扩增”的过程从大容量抗体库中筛选特异性抗结核分枝杆菌Acr蛋白的抗体,并对可变区序列进行了测序分析.将特异性的噬菌体抗体感染HB2151菌,经IPTG诱导表达,制备了抗结核分枝杆菌Acr蛋白的可溶性单链抗体;对其序列和抗原结合活性进行分析鉴定.结果:经过4轮筛选,获得了43个与结核分枝杆菌Acr蛋白结合的阳性克隆,其中29个特异结合的克隆;测序分析有26不同的可变区片段;通过可溶性单链抗体(scFv)表达筛选到14株特异性结合Acr蛋白的可溶性单链抗体克隆;经过基因测序,分析了可变区基因的亚群.成功制备了可溶性单链抗体.Westren blotting分析证实筛选的人源单链抗体能与天然蛋白结合.结论:利用单链大容量抗体库获得抗结核分枝杆菌Acr蛋白的噬菌体抗体并且成功制备抗结核分枝杆菌Acr天然蛋白的可溶性单链抗体,为今后的研究和应用奠定基础.     

抗破伤风类毒素单抗可变区基因的克隆及在大肠杆菌中表达的三种工程抗体

我们采用RT-PCR,从小鼠杂交瘤细胞中扩增并克隆了抗破伤风类毒素(TT)抗体轻、重链可变区,重链Fd区基因,测定了其VH、Vk序列。并在大肠杆菌中表达了Fd片段,ELISA分析的结果表明Fd片段具有抗原结合的能力,但特异性很差。进一步采用SOE,和PCR技术,将VH、VK基因与ScFv连接片段组装成单链抗体(ScFv)基因片段,以及将人重链CH1和Fab基因连接片段组装成Fab基因片段。将它们分别插入含噬菌体fd外壳蛋白3基因的phagem-id pHEN 1中,在辅助噬菌体M 13-VCS作用下,噬菌体表面表达了抗TT的噬菌体单链抗体(phage-ScFv)与噬菌体Fab(phage-Fab),经ELISA检测,表明它们都能与TT特异结合。     

苏云金芽胞杆菌cryⅡ基因的克隆和表达

分离的苏云金芽胞杆菌(Bacillus-thuringiensis)YBT-791对鳞翅目小菜蛾(Plutellaxylostella)有毒力,将其质粒DNA提纯,经HindⅢ酶切后与杀虫晶体蛋白cryⅡ基因探针杂交,显示出分子量分别为5kb和9．4kb两条DNA阳性片段。把5kb的DNA阳性片段克隆到pUCl8的HindⅢ位点上并转化大肠杆菌TGl,经酶切和杂交检测,证明斑点杂交阳性克隆子中含有5kb的cryI片段。把这个含cryⅡ基因的5kbHindⅢ片段进行亚克隆,将4kb的BamHI－Pstl酶切片段插入穿梭载体pXl61中,并用电脉冲法克隆于苏云金杆菌不产伴胞晶体的突变株中,得到产生单一cry Ⅱ基因编码的杀虫晶体蛋白的克隆菌株M一5。经电镜观察,该克隆菌株能形成出发菌YBT－791多种形态伴胞晶体中的一种方形伴胞晶体;经免疫双扩试验,它只能与Cry Ⅱ晶体蛋白抗血清形成沉淀线;经SDS—PAGE电泳,克隆菌的伴胞晶体只含有一种65kDa的晶体蛋白。生物测定结果表明它既对鳞翅目小菜蛾(Piutella xylostella)有毒性,又对双翅目致倦库蚊(Culex quinquefasciatus)有毒性。     

噬菌体呈现技术制备结肠癌抗独特型抗体

 以纯化的鼠抗人结肠癌细胞单克隆抗体 (简称单抗 )MC5与钥孔血蓝素 (KLH)的交联物经腹腔免疫Balb c小鼠 ,取脾分离mRNA .RT PCR分别扩增抗体重、轻链可变区基因片段 (VH 和VLcD NA ,大小分别约为 340bp和 32 0bp) ,二者经linkerDNA连接形成ScFv(singlechainvariablefragment)DNA(约 75 0bp) .将ScFvDNA与噬菌粒载体pCANTAB5E的连接产物转化于大肠杆菌TG1,经辅助噬菌体M13KO7感染后 ,获得重组噬菌体抗体ScFv文库 .以单抗MC5对ScFv文库进行 4轮亲和筛选后 ,随机挑取 80个克隆经酶联免疫吸附实验 (ELISA)筛选出 2 2个呈现ScFv形式抗独特型抗体(抗 IdScFv)的噬菌体单克隆 .竞争抑制实验表明 ,在 2 2个阳性克隆中有 4个克隆所呈现的抗 IdScFv属β或γ型 .针对单抗MC5的噬菌体呈现型抗 IdScFv的制备 ,为筛选新的结肠癌重组抗 Id瘤苗候选分子奠定了基础     

Construction of human Fab (gamma1/kappa) library and identification of human monoclonal Fab possessing neutralizing potency against Japanese encephalitis virus

A combinatorial human Fab library was constructed using RNAs from peripheral blood lymphocytes obtained from Japanese encephalitis virus hyper-immune volunteers on pComb3H phagemid vector. The size of the constructed Fab library was 3.3x10(8) Escherichia coli transformants. The library was panned 3 times on the purified Japanese encephalitis virus (JEV) virion, and phage clones displaying JEV antigen-specific Fab were enriched. The enriched phage pool was then screened for clones producing Fab molecule with JEV neutralizing activity by the focus reduction-neutralizing test. Among 188 randomly selected clones, 9 Fab preparations revealed neutralizing activities against JEV strain Nakayama. An E. coli transformed with TJE12B02 clone, which produced human monoclonal Fab with the highest neutralizing activity was cultured in a large scale, and the Fab molecule was purified using affinity chromatography. The purified FabTJE12B02 showed the 50% focus reduction endpoint at the concentration of 50.2 microg/ml (ca. 1,000 nM) when JEV strain Nakayama was used. The FabTJE12B02 recognized E protein of JEV strain Nakayama, and the dissociation equilibrium constant (Kd) of the FabTJE12B02 against purified JEV antigen was calculated as 1.21x10(-8) M. Sequence analysis demonstrated that TJE12B02 used a VH sequence homologous to the VH3 family showing 88.8% homology to germline VH3-23, and used a Vkappa sequence homologous to the VkappaII subgroup showing 92.8% homology to germline A17.     

Bacterial expression and purification of the Fab fragment of a monoclonal antibody specific for the low-density lipoprotein receptor-binding site of human apolipoprotein E.

We report the bacterial expression and the purification of a monoclonal antibody (mAb) specific for an epitope that coincides with the LDL receptor (LDLr)-binding domain of human apolipoprotein E (apoE). This antibody resembles the LDLr in its primary structure and its specificity for apoE variants. The recombinant Fab (rFab) fragment of mAb 2E8, consisting of the entire light chain and the Fd portion of the heavy chain, was expressed in Escherichia coli and purified to homogeneity. Purification was facilitated by including a five-histidine carboxyl-terminal extension on the Fd chain. A 5- to 10-fold difference in yield of the antibody was observed when the plasmid was expressed in two different strains of E. coli. Typically 2-6 mg of rFab per liter of culture medium was recovered in the periplasm of the TG1 strain and less than 1 mg was recovered in the periplasm of the XL1-Blue strain. Culture temperatures above 35 degrees C or inclusion of sucrose in the medium reduced rFab yields. The 2E8 rFab was indistinguishable from Fab prepared from 2E8 hybridoma-generated IgG with respect to its affinity and fine specificity. We are using this system to express a panel of 2E8 variant Fabs that will be used as probes to establish the structural features responsible for the binding of apoE to the LDLr.     

Construction of human Fab library and isolation of monoclonal Fabs with rabies virus-neutralizing ability

A combinatorial human Fab library was constructed using RNAs from peripheral blood lymphocytes of 6 rabies vaccine-boosted volunteers using pComb3X phagemid vector. The size of the constructed library was approximately 7.0 x 10(7) Escherichia coli transformants. The library was selected against purified rabies virus (RV) virion or purified RV glycoprotein for isolation of phages displaying RVneutralizing human Fab antibody. Among 132 selected clones, two Fab preparations revealed neutralizing activities against RV strain CVS when assayed in the rapid fluorescent focus inhibition test (RFFIT). The Fab preparation EP5G3 exhibited neutralizing activity with an infected cell count reduction of 76% at a dilution of 1: 2, and of 20% at a dilution of 1: 4. The Fab preparation GD2D12 also exhibited neutralizing activity with a 57% reduction at 1: 2 and 41% reduction at 1: 4. In the co-immunoprecipitation using strain CVS, the RV glycoprotein was precipitated in reactions with both Fab preparations. The RV neutralizing ability of the Fab preparations described in the study were not directly correlated with their binding specificity for RV antigens detected by ELISA.     

A fully synthetic human Fab antibody library based on fixed VH/VL framework pairings with favorable biophysical properties

This report describes the design, generation and testing of Ylanthia, a fully synthetic human Fab antibody library with 1.3E+11 clones. Ylanthia comprises 36 fixed immunoglobulin (Ig) variable heavy (VH)/variable light (VL) chain pairs, which cover a broad range of canonical complementarity-determining region (CDR) structures. The variable Ig heavy and Ig light (VH/VL) chain pairs were selected for biophysical characteristics favorable to manufacturing and development. The selection process included multiple parameters, e.g., assessment of protein expression yield, thermal stability and aggregation propensity in fragment antigen binding (Fab) and IgG1 formats, and relative Fab display rate on phage. The framework regions are fixed and the diversified CDRs were designed based on a systematic analysis of a large set of rearranged human antibody sequences. Care was taken to minimize the occurrence of potential posttranslational modification sites within the CDRs. Phage selection was performed against various antigens and unique antibodies with excellent biophysical properties were isolated. Our results confirm that quality can be built into an antibody library by prudent selection of unmodified, fully human VH/VL pairs as scaffolds.